SCHEMBL6245709

SCHEMBL6245709

COC(=O)c1ccc(CNC(=O)c2cc(C(=O)NCc3ccc(C(=O)OC)cc3)cc(C(=O)NCc3ccc(C(=O)OC)cc3)c2)cc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.63
KMT2A Q03164 2/20 0.63
SMN1; SMN2 Q16637 2/20 0.63
CYP2C9 P11712 1/20 0.59
NPC1 O15118 4/20 0.56
RAB9A P51151 4/20 0.56
NR1H4 Q96RI1 3/20 0.56
LOXL2 Q9Y4K0 1/20 0.56
KDM4E B2RXH2 1/20 0.55
NAMPT P43490 1/20 0.54
CA1 P00915 1/20 0.54
CA2 P00918 1/20 0.54
L3MBTL1 Q9Y468 2/20 0.54
EPHX2 P34913 1/20 0.54
MMP13 P45452 1/20 0.53
TDP1 Q9NUW8 1/20 0.53
MAPT P10636 1/20 0.53
ALDH1A1 P00352 2/20 0.52
EGFR P00533 1/20 0.52
SRC P12931 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28684197 0.87 EPHX2 (0.68) MEN1KMT2ASMN1; SMN2CYP2C9NPC1
SCHEMBL2833527 0.87 KMT2A (0.68) MEN1KMT2ASMN1; SMN2NPC1RAB9A
SCHEMBL21454776 0.87 MEN1 (0.77) MEN1KMT2ASMN1; SMN2NPC1RAB9A
SCHEMBL20804537 0.87 SMN1; SMN2 (0.60) MEN1KMT2ASMN1; SMN2NPC1RAB9A
SCHEMBL13947386 0.87 ALDH1A1 (0.66) MEN1KMT2ASMN1; SMN2CYP2C9NPC1
SCHEMBL4241219 0.85 MEN1 (0.63) MEN1KMT2ASMN1; SMN2CYP2C9NPC1
SCHEMBL4234328 0.85 MEN1 (0.63) MEN1KMT2ASMN1; SMN2CYP2C9NPC1
SCHEMBL26032304 0.85 LOXL2 (0.75) MEN1KMT2ASMN1; SMN2CYP2C9NPC1
SCHEMBL18259860 0.85 KMT2A (0.63) MEN1KMT2ASMN1; SMN2CYP2C9NPC1
SCHEMBL2839345 0.85 MEN1 (0.68) MEN1KMT2ASMN1; SMN2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020103183-A1 Benzene tricarboxylic acid derivatives as insulin receptor activators TELIK, INC. 2002-08-01 US claimed
EP-1315695-B1 BENZENE TRICARBOXYLIC ACID AMIDES AS INSULIN RECEPTOR ACTIVATORS TELIK INC (US) 2005-07-13 EP disclosed
US-6600069-B2 Insulin receptor kinase activators; treating hyperglycemia; 4-((3,5-bis(N-(4-sulfophenyl)carbamoyl)phenyl)carbonylamino)-benzenesulfonic acid, for example TELIK, INC. 2003-07-29 US disclosed
US-20020103183-A1 Benzene tricarboxylic acid derivatives as insulin receptor activators TELIK, INC. 2002-08-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020103183-A1 Benzene tricarboxylic acid derivatives as insulin receptor activators GPR119, INSR, IRS1 MEN1 4726/4885KMT2A 3545/4885SMN1; SMN2 4083/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.